Evaluating Mucilage from Aloe Barbadensis Miller as a Pharmaceutical Excipient for Sustained-Release Matrix Tablets - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Evaluating Mucilage from Aloe Barbadensis Miller as a Pharmaceutical Excipient for Sustained-Release Matrix Tablets
Natural gums and mucilage have been widely explored as pharmaceutical excipients. The goal of this study was to extract mucilage from the leaves of Aloe barbadensis Miller and to study its functionality as an excipient in pharmaceutical sustained-release tablet formulations.

Pharmaceutical Technology

4. G.M. Khan and Z. Jiabi, "Formulation and In-vitro Evaluation of Ibuprofen-carbopol 974P-NF Controlled Release Matrix Tablets III: Influence of Co-Excipients on Release Rate of the Drug." J. Control Release 54 (2), 185–190 (1998).

5. L. Genc, H. Bilac, and E. Guler, "Studies on Controlled Release Dimenhydrinate from Matrix Tablet Formulations," Pharm. Acta Helv. 74 (1), 43–49 (1999).

6. G.T. Kulkarni et al., "Evaluation of Binding Properties of Plantago ovata and Trigonella foenum graecum Mucilage," Indian Drugs 39 (8), 422–425 (2002).

7. B. Anroop et al., "Studies on Ocimum gratissimum Seed Mucilage: Evaluation of Suspending Properties," Indian J. Pharm. Sci. 67 (2), 206–209 (2005).

8. P.D. Bharadia et al., "A Preliminary Investigation on Sesbania Gum as a Pharmaceutical Excipient," Int. J. Pharm. Excipient 1 (4), 102–105 (2004).

9. H. Pawar, and P.M. D'Mello, "Isolation of Seed Gum from Cassia tora and Preliminary Studies of its Application as a Binder for Tablets," Indian Drugs 41 (8), 465–468 (2004).

10. K. Gowthamarajan et al., "Evaluation of Borassus flabellifer Mucilage as Gelling Agent," Indian Drugs 40 (11), 640–644 (2003).

11. C. Evans, Trease & Evans—Pharmacognosy (Elsevier Ltd., New York 15th ed., 2002), pp. 240–244.

12. J. Anjaria, M. Parabia, and S. Dwivedi, Ethnovet Heritage: Indian Ethnoveterinary Medicine an Overview. (Pathik Enterprise, Ahmedabad, India, 1st ed., 2002), p. 194.

13. Goodman's and Gilman's the Pharmacological Basis of Therapeutics, J.G. Hardman, L.E. Limbird, Eds. (McGraw Hill, New York, 9th ed., 1995).

14. P. D. Fowler et al., "Plasma and Synovial Fluid Concentration of Diclofenac Sodium and its Major Hydroxylated Metabolites during Long-term Treatment of Rheumatoid Arthritis," Eur. J. Clin. Pharmacology 25 (3), 389–394 (1983).

15. J.V. Willis, M.J. Kendall, and D.B. Jack, "The Influence of Food on the Absorption of Diclofenac after Single and Multiple Oral Doses," Eur. J. Clin. Pharmacology 19 (1), 33–37 (1981).

16. S.K. Baveja, K.V. Rao, and J. Arora, "Examination of Natural Gums and Mucilages as Sustaining Agents in Tablet Dosage Forms," Indian J. Pharm. Sci. 50 (2), 89–92 (1988).

17. Ministry of Health and Family Welfare, Government of India, Indian Pharmacopoeia (The Controller of Publications, New Delhi, 4th ed., 1996), p. A-89.

18. F.E. Bowen and W.A. Vadino, "A Simple Method for Differentiating Starches," Drug Dev. Ind. Pharm. 10, 505–511 (1984).

19. P. J. Sink, Martin's Physical Pharmacy and Pharmaceutical Science (B. I. Publications Pvt. Ltd., New Delhi, 5th ed., 2006), pp. 553–556.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here